

Augusto Villanueva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8897328/publications.pdf>

Version: 2024-02-01

144
papers

28,029
citations

13827

67
h-index

9073

144
g-index

155
all docs

155
docs citations

155
times ranked

24638
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. <i>Gut</i> , 2023, 72, 129-140.	6.1	90
2	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. <i>Gut</i> , 2023, 72, 736-748.	6.1	42
3	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. <i>Gut</i> , 2022, 71, 2069-2080.	6.1	24
4	Digital-resolution and highly sensitive detection of multiple exosomal small RNAs by DNA toehold probe-based photonic resonator absorption microscopy. <i>Talanta</i> , 2022, 241, 123256.	2.9	12
5	Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. <i>Molecular Oncology</i> , 2022, 16, 665-682.	2.1	3
6	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2297-2305.	3.2	8
7	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. <i>Nature Cancer</i> , 2022, 3, 386-401.	5.7	126
8	Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2022, 42, 188-201.	1.8	6
9	DNA Methylation Profiling of Human Hepatocarcinogenesis. <i>Hepatology</i> , 2021, 74, 183-199.	3.6	42
10	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	3.6	235
11	Biomarkers for Hepatobiliary Cancers. <i>Hepatology</i> , 2021, 73, 115-127.	3.6	104
12	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 140-151.	2.6	77
13	Signaling pathways in hepatocellular carcinoma. <i>Advances in Cancer Research</i> , 2021, 149, 63-101.	1.9	56
14	The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. <i>Cancers</i> , 2021, 13, 659.	1.7	25
15	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone-Dependent Release of Circulating Tumor DNA. <i>Hepatology Communications</i> , 2021, 5, 1095-1105.	2.0	7
16	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. <i>PLoS Genetics</i> , 2021, 17, e1009589.	1.5	15
17	Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. <i>JHEP Reports</i> , 2021, 3, 100237.	2.6	32
18	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2021, 160, 2572-2584.	0.6	91

#	ARTICLE	IF	CITATIONS
19	Novel non-protein biomarkers for early detection of hepatocellular carcinoma. <i>Engineering</i> , 2021, 7, 1369-1369.	3.2	1
20	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020). <i>Gastroenterology</i> , 2021, 161, 879-898.	0.6	123
21	Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100364.	2.6	9
22	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 6.	18.1	2,757
23	Tumour evolution in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 139-152.	8.2	501
24	Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing. <i>BMC Medicine</i> , 2020, 18, 200.	2.3	25
25	Liquid biopsy in the clinical management of hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 2025-2034.	6.1	77
26	Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors. <i>Scientific Reports</i> , 2020, 10, 5062.	1.6	5
27	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 73, 315-327.	1.8	164
28	Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2020, 26, 823-831.	1.3	25
29	Intratumoral heterogeneity and clonal evolution in liver cancer. <i>Nature Communications</i> , 2020, 11, 291.	5.8	230
30	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <i>Gut</i> , 2019, 68, 1065-1075.	6.1	195
31	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. <i>British Journal of Cancer</i> , 2019, 121, 340-343.	2.9	62
32	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 4326-4330.	0.4	99
33	Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2019, 14, 62-65.	1.0	21
34	A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. <i>Histopathology</i> , 2019, 74, 718-730.	1.6	9
35	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1506-1519.	1.9	16
36	The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. <i>JHEP Reports</i> , 2019, 1, 120-130.	2.6	43

#	ARTICLE	IF	CITATIONS
37	Î²-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1124-1141.	7.7	498
38	Mitohormesis Primes Tumor Invasion and Metastasis. <i>Cell Reports</i> , 2019, 27, 2292-2303.e6.	2.9	69
39	Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. <i>Hepatology</i> , 2019, 70, 2107-2122.	3.6	26
40	Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. <i>Breast Cancer Research</i> , 2019, 21, 56.	2.2	19
41	Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1450-1462.	13.9	2,966
42	The Impact of Translational Research in Hepatology. <i>Clinical Liver Disease</i> , 2019, 13, 29-33.	1.0	2
43	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. <i>Journal of Hepatology</i> , 2019, 70, 1262-1277.	1.8	150
44	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. <i>Oncogene</i> , 2018, 37, 3740-3752.	2.6	89
45	Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma. <i>Oncoscience</i> , 2018, 5, 209-211.	0.9	11
46	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 11570.	1.6	64
47	Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. <i>Gut</i> , 2017, 66, 530-540.	6.1	161
48	Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. <i>Journal of Hepatology</i> , 2017, 66, 952-961.	1.8	120
49	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. <i>Gastroenterology</i> , 2017, 153, 812-826.	0.6	650
50	Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. <i>Gastroenterology</i> , 2017, 152, 745-761.	0.6	838
51	Divergent evolutionary trajectories in transplanted tumor models. <i>Nature Genetics</i> , 2017, 49, 1565-1566.	9.4	13
52	Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 1222-1231.	1.8	121
53	Diagnostic and Prognostic Performance of Liquid Biopsy in Hepatocellular Carcinoma. <i>Current Clinical Pathology</i> , 2017, , 125-135.	0.0	3
54	Progress towards molecular patient stratification of hepatocellular carcinoma: Lost in translation?. <i>Journal of Hepatology</i> , 2017, 67, 893-895.	1.8	4

#	ARTICLE	IF	CITATIONS
55	Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-24.	0.1	0
56	Molecular profiling of liver cancer heterogeneity. Discovery Medicine, 2017, 24, 117-125.	0.5	3
57	Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver diseaseâ€hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. Clinical Liver Disease, 2016, 8, 100-104.	1.0	20
58	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell, 2016, 30, 879-890.	7.7	172
59	The transition from inflammation to cancer in the liver. Clinical Liver Disease, 2016, 8, 89-93.	1.0	25
60	Selected summary for the 2015 Asiaâ€Pacific Primary Liver Cancer Expert Meeting (APPLE). Hepatic Oncology, 2016, 3, 5-8.	4.2	0
61	Nontumor Prognostic Factors in Hepatocellular Carcinoma. , 2016, , 139-147.		2
62	IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology, 2016, 151, 1192-1205.	0.6	103
63	Effect of HCV clearance with direct-acting antiviral agents on HCC. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 561-562.	8.2	67
64	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. Journal of Hepatology, 2016, 65, 1031-1042.	1.8	219
65	Liver capsule: Molecularâ€based signatures in hepatocellular carcinoma. Hepatology, 2016, 63, 2018-2018.	3.6	9
66	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut, 2016, 65, 1754-1764.	6.1	108
67	Circulating tumor cells and cholangiocarcinoma. Hepatology, 2016, 63, 23-25.	3.6	4
68	Clinical Trial Watch: Reports from the Liver MeetingÂ®, AASLD, San Francisco, November 2015. Journal of Hepatology, 2016, 64, 1428-1445.	1.8	3
69	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature Reviews Clinical Oncology, 2015, 12, 408-424.	12.5	456
70	DNA methylationâ€based prognosis and epidrivers in hepatocellular carcinoma. Hepatology, 2015, 61, 1945-1956.	3.6	367
71	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 806-818.e10.	0.6	109
72	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology, 2015, 149, 1226-1239.e4.	0.6	980

#	ARTICLE	IF	CITATIONS
73	Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. <i>Journal of Hepatology</i> , 2015, 63, 753-762.	1.8	5
74	DNA-PKâ€™A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. <i>Clinical Cancer Research</i> , 2015, 21, 925-933.	3.2	74
75	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	9.4	1,372
76	Intratumor Molecular and Phenotypic Diversity in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 1786-1788.	3.2	73
77	The future of patient-derived tumor xenografts in cancer treatment. <i>Pharmacogenomics</i> , 2015, 16, 1671-1683.	0.6	43
78	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. <i>Gut</i> , 2015, 64, 1296-1302.	6.1	70
79	The usual SASpects of liver cancer. <i>Aging</i> , 2015, 7, 348-349.	1.4	4
80	Liquid biopsy in liver cancer. <i>Discovery Medicine</i> , 2015, 19, 263-73.	0.5	40
81	Transplantation for hepatocellular carcinoma-worth waiting for?. <i>Liver Transplantation</i> , 2014, 20, 871-873.	1.3	1
82	Mutational landscape of HCCâ€™the end of the beginning. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 73-74.	12.5	108
83	UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2014, 25, 196-209.	7.7	261
84	VEGF Signaling in Cancer Treatment. <i>Current Pharmaceutical Design</i> , 2014, 20, 2834-2842.	0.9	74
85	Prognostic Gene Expression Signature for Patients With Hepatitis Câ€™Related Early-Stage Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1024-1030.	0.6	195
86	Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with <i>EGFR</i> . <i>Hepatology</i> , 2013, 57, 120-130.	3.6	52
87	Rethinking future development of molecular therapies in hepatocellular carcinoma: A bottom-up approach. <i>Journal of Hepatology</i> , 2013, 59, 392-395.	1.8	20
88	Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. <i>Gastroenterology</i> , 2013, 144, 829-840.	0.6	438
89	Medical therapies for hepatocellular carcinoma: a critical view of the evidence. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 34-42.	8.2	277
90	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. <i>Gastroenterology</i> , 2013, 145, 176-187.	0.6	302

#	ARTICLE	IF	CITATIONS
91	Genetically engineered mouse models: future tools to predict clinical trial results in oncology?. <i>Future Oncology</i> , 2013, 9, 767-770.	1.1	1
92	Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension. <i>World Journal of Gastroenterology</i> , 2013, 19, 1193.	1.4	34
93	Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. <i>Hepatology</i> , 2012, 56, 2416-2419.	3.6	16
94	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 4997-5007.	3.2	251
95	Cell population genetics and deep sequencing: A novel approach for drivers discovery in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 1198-1200.	1.8	3
96	Molecular epidemiology in HCV-related hepatocellular carcinoma: First steps. <i>Journal of Hepatology</i> , 2012, 57, 213-214.	1.8	6
97	Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. <i>Journal of Hepatology</i> , 2012, 56, 1343-1350.	1.8	181
98	Why men are at higher risk for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , 2012, 57, 453-454.	1.8	38
99	microRNAs: New ways to block tumor angiogenesis?. <i>Journal of Hepatology</i> , 2012, 57, 490-491.	1.8	9
100	Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 1824-1826.	3.2	86
101	Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. <i>Hepatology</i> , 2012, 56, 1361-1370.	3.6	31
102	Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice. <i>Gastroenterology</i> , 2012, 143, 1660-1669.e7.	0.6	262
103	Emerging Signaling Pathways in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2012, 1, 83-93.	4.2	169
104	Gene Signatures in the Management of Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 473-485.	0.8	68
105	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1501-1512.e2.	0.6	389
106	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. <i>Gastroenterology</i> , 2011, 140, 1618-1628.e16.	0.6	205
107	Hepatocellular Carcinoma Enters the Sequencing Era. <i>Gastroenterology</i> , 2011, 141, 1943-1945.	0.6	5
108	Targeted Therapies for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1410-1426.	0.6	408

#	ARTICLE	IF	CITATIONS
109	Signaling Pathways in Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 18-23.	0.9	39
110	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1325-1331.	1.8	133
111	Depicting the role of TP53 in hepatocellular carcinoma progression. <i>Journal of Hepatology</i> , 2011, 55, 724-725.	1.8	54
112	Molecular Pathogenesis of Hepatocellular Carcinoma. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 821-825.	1.4	47
113	Carcinogen-induced hepatic tumors in KLF6+/Δ mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. <i>Hepatology</i> , 2011, 54, 522-531.	3.6	39
114	Inherited hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 725-734.	1.0	28
115	New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers. <i>Clinical Cancer Research</i> , 2010, 16, 4688-4694.	3.2	114
116	Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. <i>Seminars in Liver Disease</i> , 2010, 30, 035-051.	1.8	267
117	miRNA Delivery: Emerging Therapy for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2010, 138, 1202-1204.	0.6	13
118	Cancer gene discovery in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010, 52, 921-929.	1.8	173
119	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockade. <i>Journal of Hepatology</i> , 2010, 52, 550-559.	1.8	211
120	Genomic tracing of the elusive liver cancer ancestor. <i>Journal of Hepatology</i> , 2010, 53, 578-579.	1.8	1
121	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. <i>Annual Review of Medicine</i> , 2010, 61, 317-328.	5.0	229
122	Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2009, 69, 7385-7392.	0.4	978
123	Lymphotoxins: New Targets for Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2009, 16, 272-273.	7.7	17
124	A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. <i>Nature Biotechnology</i> , 2009, 27, 264-274.	9.4	194
125	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009, 51, 725-733.	1.8	206
126	Molecular profiling to predict hepatocellular carcinoma outcome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 101-103.	1.4	37

#	ARTICLE	IF	CITATIONS
127	Pathogenesis of hepatocellular carcinoma and molecular therapies. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 186-194.	1.0	118
128	Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. <i>Journal of Clinical Investigation</i> , 2009, 119, 465-477.	3.9	298
129	Ras Promotes Growth by Alternative Splicing-Mediated Inactivation of the KLF6 Tumor Suppressor in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 134, 1521-1531.	0.6	96
130	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1972-1983.e11.	0.6	644
131	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.4	589
132	Experimental models of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2008, 48, 858-879.	1.8	203
133	Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials. <i>Journal of Hepatology</i> , 2008, 49, 1-5.	1.8	35
134	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3129-3140.	1.9	1,237
135	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	13.9	1,148
136	Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. <i>Current Opinion in Oncology</i> , 2008, 20, 444-453.	1.1	60
137	Genomics and Signaling Pathways in Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2007, 27, 055-076.	1.8	491
138	Current management of liver cancer. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 444-446.	2.2	4
139	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. <i>Gastroenterology</i> , 2006, 131, 1758-1767.	0.6	379
140	Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 79-83.	0.8	20
141	Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1535-1547.	1.9	341
142	Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal. <i>Liver Transplantation</i> , 2006, 12, 1747-1754.	1.3	16
143	Safety of Percutaneous Ethanol Injection as Neoadjuvant Therapy for Hepatocellular Carcinoma in Waiting List Liver Transplant Candidates. <i>Transplantation Proceedings</i> , 2005, 37, 3871-3873.	0.3	21
144	Update in the Therapeutic Management of Irritable Bowel Syndrome. <i>Digestive Diseases</i> , 2001, 19, 244-250.	0.8	9